| Description | Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH). |
| Synonyms | PF-06865571 |
| molecular weight | 407.42 |
| Molecular formula | C21H21N5O4 |
| CAS | 2186700-33-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 120 mg/mL(294.54 mM), Sonication is recommended. |
| References | 1. PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS |